Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

Inclusion Criteria

• •You are expected to be alive in the 12 weeks.
• •You are at least 18 years old.
• •You live close enough to the doctor's office to attend all of your required visits.
• •You have not been treated with chemotherapy for your prostate cancer (cohort 1).
• •Must have evidence of androgen-independent PSA-progressive disease without a history of or current (as judged by the investigator) clinical or radiographic evidence of metastatic disease with castrate levels of testosterone (\<50 ng/dL) maintained by luteinizing hormone-releasing hormone (LHRH) agonist or bilateral orchiectomy following standard anti-androgen withdrawal. NOTE: PSA progression is defined as have rising PSA values of \<=5 ng/mL (at least 3 measurements 1 week apart) with castrate levels of testosterone \<50 ng/dL following appropriate antiandrogen withdrawal, without evidence of metastases. (cohort 1)
• •No prior systemic chemotherapy for prostate cancer. No prior chemotherapy for any other indication within 2 years of study entry. NOTE: Participants previously treated with chemotherapy in the adjuvant/neoadjuvant setting were not be eligible. (cohort 1)
• •You have had one prior docetaxel-based chemotherapy regimen (cohort 2).
• •You have evidence of metastatic prostate cancer with bone or soft tissue disease (cohort 2).